Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
KYMR 
Kymera Therapeutics Inc (KYMR)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/26/2025: KYMR (4-star) is a STRONG-BUY. BUY since 73 days. Simulated Profits (72.00%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $115.64
1 Year Target Price $115.64
| 14 | Strong Buy |
| 3 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 197.43% | Avg. Invested days 36 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/26/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.51B USD | Price to earnings Ratio - | 1Y Target Price 115.64 |
Price to earnings Ratio - | 1Y Target Price 115.64 | ||
Volume (30-day avg) 20 | Beta 2.29 | 52 Weeks Range 19.45 - 103.00 | Updated Date 12/27/2025 |
52 Weeks Range 19.45 - 103.00 | Updated Date 12/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.6 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3207.89% |
Management Effectiveness
Return on Assets (TTM) -19.21% | Return on Equity (TTM) -32.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6083835875 | Price to Sales(TTM) 148.75 |
Enterprise Value 6083835875 | Price to Sales(TTM) 148.75 | ||
Enterprise Value to Revenue 139.11 | Enterprise Value to EBITDA -9.49 | Shares Outstanding 79999027 | Shares Floating 48455511 |
Shares Outstanding 79999027 | Shares Floating 48455511 | ||
Percent Insiders 2.25 | Percent Institutions 106.85 |
Upturn AI SWOT
Kymera Therapeutics Inc
Company Overview
History and Background
Kymera Therapeutics, Inc. was founded in 2017 by Sunesis Pharmaceuticals, Inc. and has since emerged as a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule drugs that degrade disease-causing proteins. The company utilizes its proprietary Pegasusu2122 platform for targeted protein degradation. Key milestones include the initiation of clinical trials for its lead programs and significant partnerships.
Core Business Areas
- Therapeutic Development: Kymera Therapeutics focuses on developing small molecule drugs that target and degrade specific disease-causing proteins implicated in various conditions. Their platform enables the identification and development of novel therapeutics through targeted protein degradation.
Leadership and Structure
The company is led by a management team with extensive experience in drug discovery, development, and commercialization within the biopharmaceutical industry. The organizational structure is typical of a clinical-stage biotech, with functional teams dedicated to research, clinical operations, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- KY-1001 (Pegasomeu2122): A novel IRAK4 degrader for autoimmune and inflammatory diseases. Currently in clinical trials. Competitors include companies developing small molecule inhibitors or biologics targeting inflammatory pathways.
- KY-1002 (Pegasomeu2122): A novel STAT6 degrader for autoimmune and inflammatory diseases. Currently in pre-clinical development. Competitors are similar to KY-1001.
- KY-2001 (Pegasomeu2122): A novel MDM2 degrader for oncology indications. Currently in pre-clinical development. Competitors include companies developing MDM2 inhibitors or other cancer therapeutics.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in the areas of autoimmune diseases, inflammatory conditions, and oncology, is characterized by significant innovation, high research and development costs, and stringent regulatory requirements. There is a strong demand for novel therapeutics with improved efficacy and safety profiles.
Positioning
Kymera Therapeutics is positioned as an innovator in the field of targeted protein degradation, a novel therapeutic modality. Its proprietary Pegasusu2122 platform offers a potential competitive advantage in discovering and developing drugs for diseases where current treatments are insufficient. The company is focused on early-stage development and strategic partnerships to advance its pipeline.
Total Addressable Market (TAM)
The TAM for Kymera Therapeutics' therapeutic areas (autoimmune diseases, inflammatory diseases, oncology) is vast, encompassing billions of dollars globally. Kymera Therapeutics is positioned to address specific unmet needs within these large markets by developing novel protein degraders.
Upturn SWOT Analysis
Strengths
- Proprietary Pegasusu2122 platform for targeted protein degradation.
- Experienced leadership team with strong scientific and business acumen.
- Focus on a novel and potentially disruptive therapeutic modality.
- Advancing pipeline with multiple clinical-stage and pre-clinical assets.
Weaknesses
- Clinical-stage company with no approved products, leading to high R&D costs and no revenue from product sales.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Potential for manufacturing and scalability challenges with novel modalities.
Opportunities
- Significant unmet medical needs in target disease areas.
- Potential for strategic partnerships and collaborations with larger pharmaceutical companies.
- Advancements in understanding disease biology and protein targets.
- Expanding applications of targeted protein degradation across various therapeutic areas.
Threats
- High failure rate in drug development, particularly in clinical trials.
- Intense competition from established pharmaceutical companies and other biotech firms.
- Evolving regulatory landscape and potential for delays in approvals.
- Patent challenges and intellectual property disputes.
Competitors and Market Share
Key Competitors
- Arcellx Inc. (X)
- Nurix Therapeutics, Inc. (NRIX)
- Cullinan Therapeutics, Inc. (CLLS)
- Verastem, Inc. (VSTM)
Competitive Landscape
Kymera Therapeutics faces competition from companies developing therapies for similar indications, as well as those employing different modalities such as small molecule inhibitors, antibodies, and gene therapies. Kymera's competitive advantage lies in its specialized expertise and platform for targeted protein degradation, offering a potentially novel mechanism of action.
Growth Trajectory and Initiatives
Historical Growth: Kymera Therapeutics' historical growth has been characterized by pipeline expansion, successful fundraising rounds to support R&D, and the advancement of its lead programs into clinical development. Growth is measured by the progression of its drug candidates through the development pipeline.
Future Projections: Future growth is projected to be driven by the successful clinical development and potential commercialization of its pipeline assets, as well as new drug discovery efforts. Analyst projections are often based on the company's ability to achieve key clinical milestones and secure strategic partnerships.
Recent Initiatives: Recent initiatives include the progression of its lead drug candidates into clinical trials, the expansion of its discovery efforts using the Pegasusu2122 platform, and strategic collaborations aimed at accelerating drug development.
Summary
Kymera Therapeutics is a promising clinical-stage biopharmaceutical company with a strong focus on targeted protein degradation. Its proprietary platform and advancing pipeline present significant growth potential, particularly in autoimmune diseases and oncology. However, like all clinical-stage biotechs, it faces high R&D costs, regulatory hurdles, and intense competition. Success hinges on successful clinical trial outcomes and effective pipeline progression.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company investor relations websites
- Financial news outlets (e.g., Bloomberg, Reuters)
- Biopharmaceutical industry research reports
- SEC filings (e.g., 10-K, 10-Q)
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial or investment advice. Past performance is not indicative of future results. Investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kymera Therapeutics Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2020-08-21 | Co-Founder, President, CEO & Director Dr. Nello Mainolfi M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 225 | Website https://www.kymeratx.com |
Full time employees 225 | Website https://www.kymeratx.com | ||
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.